Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

222701

registered interest
date	23/02/2015
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Youth Engagement Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Wallace of Saltaire on 14 August 2014 (HL1625), how many young people from the Gypsy and Traveller communities have benefited from the Youth Engagement Fund.
tabling member printed	Baroness Whitaker
uin	HL5042
answer	answer is ministerial correction date of answer 02/03/2015 answer text <p>The Youth Engagement Fund aims to support the most disadvantaged young people in society who are at risk of becoming long term NEET (Not in Education, Employment or Training). The Fund is being awarded through a competitive bidding process over two stages and we expect to announce the winning bidders in the coming weeks. Programmes will start delivering support to disadvantaged young people soon afterwards.</p> answering member printed Lord Wallace of Saltaire question first answered 02/03/2015 15:11:52 answering member 1816 label Biography information for Lord Wallace of Saltaire
tabling member	2510 label Biography information for Baroness Whitaker

222730

registered interest
date	23/02/2015
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Lord Green of Hurstpierpoint
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether Lord Green of Hurstpierpoint disclosed an interest in, and knowledge about, HSBC before he was appointed as a member of HM Treasury’s Banking Reform Committee; and when he joined and left that Committee.
tabling member printed	Lord Myners
uin	HL5071
answer	answer is ministerial correction date of answer 05/03/2015 answer text <p>Lord Green was a member of the Banking Reform Committee for the period 11 January 2011 to 11 December 2013. His interest in HSBC is a matter of public record. As was the case under previous administrations, information relating to the proceedings of Cabinet Committees, including when and how often they meet and which Ministers have attended, is generally not disclosed.</p> answering member printed Lord Wallace of Saltaire grouped question UIN HL5231 question first answered 05/03/2015 16:59:18 answering member 1816 label Biography information for Lord Wallace of Saltaire
tabling member	3869 label Biography information for Lord Myners

222755

registered interest
date	23/02/2015
answering body	HM Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Financial Markets
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they support the revision to the European Union Markets in Financial Instruments Directive to cut the maximum allowable delay for reporting large equity trades from three days to the end of each trading day; and whether they will also introduce requirements to ensure that brokers and asset managers do not pass on costs for their errors to pension funds.
tabling member printed	Lord Mendelsohn
uin	HL5096
answer	answer is ministerial correction date of answer 09/03/2015 answer text <p>The regulatory technical standards under the Markets in Financial Instruments Directive II will set the details of the post-trade transparency rules, including the allowable length of delay for reporting trades. These technical standards have not yet been adopted and are currently being consulted on by the European Securities and Markets Authority.</p><p> </p><p> </p><p> </p><p>The Financial Conduct Authority has described examples of good practice under conflicts of interest rules covering the allocation of the costs of trading errors between firms and their customers.</p><p> </p> answering member printed Lord Deighton question first answered 09/03/2015 17:21:48 answering member 4262 label Biography information for Lord Deighton
tabling member	4286 label Biography information for Lord Mendelsohn

222787

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Chemicals
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government further to the Written Answer by the Parliamentary Under-Secretary of State for Business, Innovation and Skills, Mr George Freeman, on 14 January (HC220047), what are the necessary steps that would be required for laboratory reagents to be licensed for use as medicinal products.
tabling member printed	Lord Alton of Liverpool
uin	HL5128
answer	answer is ministerial correction date of answer 05/03/2015 answer text <p>A laboratory reagent that does not make medicinal claims is not a medicinal product <em>per se </em>; however, if a company wishes to apply for a licence to use a laboratory reagent - as a medicinal product as defined in Directive 2001/83 EC they would need to submit an application for a marketing authorisation to the Licensing Authority, supported by the appropriate safety, efficacy and quality data set out in that Directive.</p><p> </p><p> </p><p> </p><p>CE marking applies to medical devices. Products meeting the definition of a medicinal product are required to obtain a marketing authorisation before they can be placed on the market. In order to obtain a marketing authorisation, all data related to quality, safety and efficacy of the product, including prior use in the relevant population should be submitted and will be evaluated by the Medicines and Healthcare products Regulatory Agency (MHRA) on behalf of the Licensing Authority. If a product already has a marketing authorisation and is in clinical use in another EU member state, the licence holder is eligible to apply for an authorisation in the United Kingdom through a Mutual Recognition procedure where the data supporting the product’s use and the evaluation report of the Member State that has approved the product will be submitted to the MHRA for a decision on approval of a UK marketing authorisation to be reached within the defined timelines of the procedure.</p><p> </p><p> </p><p> </p><p>Medicines legislation contains a provision for the use of an unlicensed medicinal product which is provided for by way of an exemption from the requirement for a marketing authorisation. In the interests of public health this exemption is narrowly drawn because these products, unlike products holding a marketing authorisation, will not have been assessed and approved against the criteria of safety, quality and efficacy. Under their terms of service, general practitioners and hospital doctors are allowed to prescribe any medicinal product, including any unlicensed medicinal product which they consider necessary to meet the clinical needs of their patients and under their clinical responsibility. They should always satisfy themselves that the medicinal products or other substances they consider appropriate for their patients can be safely prescribed, that patients are adequately monitored and that, where necessary, expert hospital supervision is available.</p><p> </p> answering member printed Earl Howe grouped question UIN HL5129 HL5130 question first answered 05/03/2015 16:36:32 answering member 2000 label Biography information for Earl Howe
tabling member	738 label Biography information for Lord Alton of Liverpool

222788

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by the Parliamentary Under-Secretary of State for Business, Innovation and Skills, Mr George Freeman, on 14 January (HC220047), what are the necessary steps that would be required for medicinal products to be licensed for use in clinical practice when the products concerned do not yet have CE marking; and how the prior use of such materials in clinical practice within other European Union Member States would affect regulation of their potential use in the United Kingdom.
tabling member printed	Lord Alton of Liverpool
uin	HL5129
answer	answer is ministerial correction date of answer 05/03/2015 answer text <p>A laboratory reagent that does not make medicinal claims is not a medicinal product <em>per se </em>; however, if a company wishes to apply for a licence to use a laboratory reagent - as a medicinal product as defined in Directive 2001/83 EC they would need to submit an application for a marketing authorisation to the Licensing Authority, supported by the appropriate safety, efficacy and quality data set out in that Directive.</p><p> </p><p> </p><p> </p><p>CE marking applies to medical devices. Products meeting the definition of a medicinal product are required to obtain a marketing authorisation before they can be placed on the market. In order to obtain a marketing authorisation, all data related to quality, safety and efficacy of the product, including prior use in the relevant population should be submitted and will be evaluated by the Medicines and Healthcare products Regulatory Agency (MHRA) on behalf of the Licensing Authority. If a product already has a marketing authorisation and is in clinical use in another EU member state, the licence holder is eligible to apply for an authorisation in the United Kingdom through a Mutual Recognition procedure where the data supporting the product’s use and the evaluation report of the Member State that has approved the product will be submitted to the MHRA for a decision on approval of a UK marketing authorisation to be reached within the defined timelines of the procedure.</p><p> </p><p> </p><p> </p><p>Medicines legislation contains a provision for the use of an unlicensed medicinal product which is provided for by way of an exemption from the requirement for a marketing authorisation. In the interests of public health this exemption is narrowly drawn because these products, unlike products holding a marketing authorisation, will not have been assessed and approved against the criteria of safety, quality and efficacy. Under their terms of service, general practitioners and hospital doctors are allowed to prescribe any medicinal product, including any unlicensed medicinal product which they consider necessary to meet the clinical needs of their patients and under their clinical responsibility. They should always satisfy themselves that the medicinal products or other substances they consider appropriate for their patients can be safely prescribed, that patients are adequately monitored and that, where necessary, expert hospital supervision is available.</p><p> </p> answering member printed Earl Howe grouped question UIN HL5128 HL5130 question first answered 05/03/2015 16:36:32 answering member 2000 label Biography information for Earl Howe
tabling member	738 label Biography information for Lord Alton of Liverpool

222789

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by the Parliamentary Under-Secretary of State for Business, Innovation and Skills, Mr George Freeman, on 14 January (HC220047), to what extent toxic materials that are not licensed by the Medicines and Healthcare products Regulatory Agency could be authorised for use in patient treatments in the absence of safety data from phase 1 clinical trials.
tabling member printed	Lord Alton of Liverpool
uin	HL5130
answer	answer is ministerial correction date of answer 05/03/2015 answer text <p>A laboratory reagent that does not make medicinal claims is not a medicinal product <em>per se </em>; however, if a company wishes to apply for a licence to use a laboratory reagent - as a medicinal product as defined in Directive 2001/83 EC they would need to submit an application for a marketing authorisation to the Licensing Authority, supported by the appropriate safety, efficacy and quality data set out in that Directive.</p><p> </p><p> </p><p> </p><p>CE marking applies to medical devices. Products meeting the definition of a medicinal product are required to obtain a marketing authorisation before they can be placed on the market. In order to obtain a marketing authorisation, all data related to quality, safety and efficacy of the product, including prior use in the relevant population should be submitted and will be evaluated by the Medicines and Healthcare products Regulatory Agency (MHRA) on behalf of the Licensing Authority. If a product already has a marketing authorisation and is in clinical use in another EU member state, the licence holder is eligible to apply for an authorisation in the United Kingdom through a Mutual Recognition procedure where the data supporting the product’s use and the evaluation report of the Member State that has approved the product will be submitted to the MHRA for a decision on approval of a UK marketing authorisation to be reached within the defined timelines of the procedure.</p><p> </p><p> </p><p> </p><p>Medicines legislation contains a provision for the use of an unlicensed medicinal product which is provided for by way of an exemption from the requirement for a marketing authorisation. In the interests of public health this exemption is narrowly drawn because these products, unlike products holding a marketing authorisation, will not have been assessed and approved against the criteria of safety, quality and efficacy. Under their terms of service, general practitioners and hospital doctors are allowed to prescribe any medicinal product, including any unlicensed medicinal product which they consider necessary to meet the clinical needs of their patients and under their clinical responsibility. They should always satisfy themselves that the medicinal products or other substances they consider appropriate for their patients can be safely prescribed, that patients are adequately monitored and that, where necessary, expert hospital supervision is available.</p><p> </p> answering member printed Earl Howe grouped question UIN HL5128 HL5129 question first answered 05/03/2015 16:36:31 answering member 2000 label Biography information for Earl Howe
tabling member	738 label Biography information for Lord Alton of Liverpool

222805

registered interest
date	23/02/2015
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	War Memorials
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Bourne of Aberystwyth on 23 February (HL4962), what maintenance has been done on the Royal Naval Division memorial; and how many water leaks there are in the monument.
tabling member printed	Lord West of Spithead
uin	HL5146
answer	answer is ministerial correction date of answer 05/03/2015 answer text <p>The Memorial Committee has recently commissioned a condition survey and a Report of its findings, together with estimates of costs for any suggested remedial works. Once the Report is available, the Foreign and Commonwealth Office and the Memorial Committee will jointly discuss appropriate funding and timelines for the essential maintenance of the monument.</p><p> </p> answering member printed Baroness Anelay of St Johns grouped question UIN HL5147 question first answered 05/03/2015 15:04:15 answering member 3474 label Biography information for Baroness Anelay of St Johns
tabling member	3834 label Biography information for Lord West of Spithead

222806

registered interest
date	23/02/2015
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	War Memorials
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Bourne of Aberystwyth on 23 February (HL4962), what is the procedure if the Committee for the Royal Naval Division memorial has no funds to refurbish the memorial.
tabling member printed	Lord West of Spithead
uin	HL5147
answer	answer is ministerial correction date of answer 05/03/2015 answer text <p>The Memorial Committee has recently commissioned a condition survey and a Report of its findings, together with estimates of costs for any suggested remedial works. Once the Report is available, the Foreign and Commonwealth Office and the Memorial Committee will jointly discuss appropriate funding and timelines for the essential maintenance of the monument.</p><p> </p> answering member printed Baroness Anelay of St Johns grouped question UIN HL5146 question first answered 05/03/2015 15:04:15 answering member 3474 label Biography information for Baroness Anelay of St Johns
tabling member	3834 label Biography information for Lord West of Spithead

222815

registered interest
date	23/02/2015
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Mediterranean Sea
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is their response to the statement by the United Nations High Commission for Refugees that a robust search and rescue operation is necessary in order to save lives in the central Mediterranean.
tabling member printed	Lord Hylton
uin	HL5156
answer	answer is ministerial correction date of answer 02/03/2015 answer text <p>The number of deaths in the Mediterranean, and on the land routes from the Horn of Africa to the Southern Mediterranean, are a tragic reminder of the great risks migrants take when they attempt the perilous journey to reach Europe.</p><p>The Government believes that the best approach lies in the continuation of Frontex (EU external border agency) Operation Triton alongside Italy’s ongoing coordination of normal search and rescue activities. Frontex has been clear that its maritime operations will assist with individual search and rescue efforts in their operational areas if called upon to do so by national search and rescue coordinators.</p><p>At the same time, the UK is continuing work with other EU countries to tackle the causes of illegal immigration and the organised trafficking gangs behind it, as well as increasing support and protection for those who need it in North and East Africa. It is action of this kind which offers the best hope of an effective response to the numbers of attempted crossings and the tragic loss of lives.</p><p> </p> answering member printed Lord Bates question first answered 02/03/2015 15:15:02 answering member 1091 label Biography information for Lord Bates
tabling member	2018 label Biography information for Lord Hylton

222851

registered interest
date	23/02/2015
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Department for Business, Innovation and Skills: Written Questions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, when he plans to provide a substantive answer to Question 222042.
tabling member constituency	Streatham
tabling member printed	Mr Chuka Umunna
uin	225006
answer	answer is ministerial correction date of answer 25/02/2015 answer text <p>Question <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2015-01-26/222042/" target="_blank">222042</a> was answered yesterday, 24 February 2015.</p><p> </p> answering member constituency Tunbridge Wells answering member printed Greg Clark question first answered 25/02/2015 13:35:17 answering member 1578 label Biography information for Greg Clark
tabling member	4128 label Biography information for Chuka Umunna